Welcome to our dedicated page for Channel Therapeutics Corporation news (Ticker: CHRO), a resource for investors and traders seeking the latest updates and insights on Channel Therapeutics Corporation stock.
The news archive for Channel Therapeutics Corporation (CHRO) captures the company’s public communications as it evolved from Chromocell Therapeutics Corporation into Channel Therapeutics and later into Pelthos Therapeutics Inc. under a new trading symbol. These releases describe a clinical-stage biotechnology company focused on non-opioid, non-addictive pain therapeutics built around selective inhibition of the sodium ion-channel NaV1.7.
Readers can find news items detailing the company’s scientific and preclinical progress, including efficacy data from in vivo animal models of eye pain and post-surgical nerve blocks. For example, Channel Therapeutics reported that its eye drop formulation CT2000 achieved predefined endpoints in animal models of acute and chronic ocular pain, and that its depot nerve block formulations demonstrated sustained effects in thermal hyperalgesia and mechanical allodynia models compared with placebo and bupivacaine.
The news flow also covers corporate developments. One release explains the name change from Chromocell Therapeutics Corporation to Channel Therapeutics Corporation and reincorporation in Nevada to better align with the company’s focus on sodium channel-based pain therapeutics. Later announcements describe a 10-for-one reverse stock split and the closing of a merger in which CHRO Merger Sub, Inc. combined with LNHC, Inc., leading to the adoption of the name Pelthos Therapeutics Inc. and a transition to trading on the NYSE American under the ticker PTHS.
In addition, the archive includes regulatory and compliance updates, such as a notice about an audit opinion with a going concern emphasis in the company’s annual report, as well as commentary on broader sodium channel pain targets in light of external clinical data. Together, these news items provide a historical record of CHRO’s scientific programs, strategic shifts, and eventual merger into Pelthos Therapeutics. Investors and researchers can use this page to review how the NaV1.7 pain programs and corporate structure evolved over time.
Summary not available.
Summary not available.